Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof

US7968577B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Bingwei Yang · Montgomery, US
• Lidia M. Doweyko · Vero Beach, US
• Wayne Vaccaro · Yardley, US
• Tram N. Huynh · Pennington, US
• David R. Tortolani · Skillman, US
• T. G. Murali Dhar · Newtown, US

Key dates

• Filing date: Oct 31, 2007
• Grant date: Jun 28, 2011
• Expiry date: Dec 23, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2601/08
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I) an enantiomer, diastereomer, tautomer, solvate (e.g. a hydrate), or a pharmaceutically-acceptable salt, thereof, wherein: M is selected from alkyl, substituted alkyl, cycloalkyl, aryl, heterocyclo, and heteroaryl, provided that if M is alkyl then R6 and R7 taken together with the carbon atom to which they are both attached are selected from a group other than cycloalkyl; Q is selected from (i) hydrogen, C1-C4 alkyl, and substituted C1-C4 alkyl; or (ii) Q and R6 are combined with the carbon atoms to which they are attached to form a 3- to 6-membered cycloalkyl; or (iii) Q and MaM are combined with the carbon atom(s) to which they are attached to form a 3- to 7-membered ring containing 1-2 heteroatoms which are independently selected from the group consisting of O, S, SO2, and N which ring may be optionally substituted with 0-2 R5 groups or carbonyl; Z is selected from cycloalkyl, heterocyclo, aryl, or heteroaryl; and M…